4 results about "Hypertrophic scar" patented technology

The application discloses a kind of active targeting hyperplastic scar's biomimetic hybrid delivery vehicle and its preparation method and application.The application uses scar fibroblast membrane protein, cationic delivery vehicle and siRNA and other materials, realizes the hybridization of cell membrane and cationic delivery vehicle by ultrasonic co-extrusion technology, and gives the immune escape and homologous targeting ability of carrier;Efficient loading of TGF-β1 siRNA is realized by using electrostatic self-assembly, so as to construct a biomimetic transdermal delivery system with active targeting characteristics.The biomimetic hybrid delivery vehicle not only provides an innovative approach for the root cause treatment of hyperplastic scar, but also opens up a new way for gene intervention of other skin fibrosis and inflammation-related diseases, and has important clinical translation value.

The application belongs to the field of new use of drugs, and more particularly relates to application of 3-Deazaadenosine in preparation of a therapeutic drug for treating hypertrophic scars. 3-Deazaadenosine is an S-adenosylhomocysteine hydrolase inhibitor, and has antiviral, anti-inflammatory and other activities. Experiments show that the compound can significantly reduce the modification level of m6A in fibroblasts in hypertrophic scar tissue, inhibit the proliferation and migration of fibroblasts, promote the apoptosis of fibroblasts, and also can reduce the expression levels of Collagen I, Collagen III and alpha-SMA in fibroblasts. Therefore, the compound can be used for preparing a drug for relieving or treating hypertrophic scars, and has important clinical application value.

This invention discloses a combination of biomarkers, a kit, and their applications for detecting hypertrophic scars (HTS). The biomarker combination includes a core biomarker and / or auxiliary biomarker 1 and / or auxiliary biomarker 2; the core biomarker is ABCC9 and CSPG4, auxiliary biomarker 1 is RGS5 and ACTA2, and auxiliary biomarker 2 is PDGFRB and TRPC6. This invention also provides a kit containing the above biomarker combination detection reagents and a drug screening method. This invention reveals for the first time that pathological pericytes are the core fibrotic cells in HTS, breaking through the traditional understanding that fibroblasts are the dominant cells. By targeting and inhibiting the abnormal activation, proliferation, and transdifferentiation of pericytes into myofibroblasts, the generation of myofibroblasts and matrix deposition are curbed at the source, providing a new strategy for precision treatment of HTS. Compared with traditional therapies, this approach has higher specificity and can achieve early molecular warning and quantitative detection of trace tissues for HTS, effectively overcoming the lag and subjectivity of clinical morphological diagnosis.

This invention provides a FAP-targeted engineered exosome for treating hypertrophic scars, its preparation method, and its application, belonging to the field of biopharmaceutical manufacturing technology. After co-incubation with an ferroptosis inducer, the FAP-targeting small molecule ligand SUC-Lys(Ac)-PEG3-UAMC1110 is covalently linked to the exosome membrane surface using an EDC / NH-mediated amide bond coupling strategy to obtain engineered exosomes. These engineered exosomes are then used to prepare microneedle patches. The microneedle patches allow the engineered exosomes to accumulate at the scar site and preferentially enter FAP-highly expressed scar fibroblasts, inhibiting their abnormal proliferation, migration, and pro-fibrotic phenotype, reducing collagen deposition, and promoting hypertrophic scar tissue remodeling. This invention combines the advantages of strong targeting, low off-target toxicity, minimally invasive drug delivery, sustained local retention, and stable efficacy, making it suitable for preparing drugs to treat or improve hypertrophic scars, and possessing good clinical translational potential.